Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 7/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.39 |
| ▸ | FEN1 | P39748 | 5/20 | 0.39 |
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746034 | 0.92 | F10 (0.43) | F10NAMPTF2PRSS1PRSS2 | |
| SCHEMBL6746061 | 0.89 | USP30 (0.42) | USP30F10ALOX5APFEN1NAMPT | |
| SCHEMBL6749793 | 0.85 | F10 (0.50) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6749844 | 0.81 | F10 (0.46) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6746084 | 0.79 | NAMPT (0.42) | F10NAMPTF2PRSS1PRSS2 | |
| SCHEMBL6750750 | 0.78 | F10 (0.49) | F10F2PRSS1 | |
| SCHEMBL7057459 | 0.77 | RORC (0.44) | USP30F10ALOX5APFEN1NAMPT | |
| SCHEMBL6750755 | 0.76 | F10 (0.47) | F10ALOX5APFEN1FPR2F2 | |
| SCHEMBL6746014 | 0.76 | F10 (0.53) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6566632 | 0.76 | F10 (0.43) | USP30F10F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220411-A1 | Oxalic acid derivatives | MERCK PATENT GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220411-A1 | Oxalic acid derivatives | F11, F2, F12 | USP30 4348/4885F10 6/4885ALOX5AP 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.